24 Chapter 1 References 1. Hay S, Jayaraman S, Truelsen T, Sorensen R, Millear A, Giussani G, et al. Global, regional, and national incidence, prevalence, and years lived with disability for 310 diseases and injuries, 1990-2015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet. 2016;388(10053):1545-602. 2. Lewis R, Gómez Álvarez CB, Rayman M, Lanham-New S, Woolf A, Mobasheri A. Strategies for optimising musculoskeletal health in the 21(st) century. BMC Musculoskelet Disord. 2019;20(1):164. 3. Allen C, Biryukov S, Giussani G, Gugnani H. Global, regional, and national disability-adjusted life-years (DALYs) for 315 diseases and injuries and healthy life expectancy (HALE), 1990-2015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet. 2016;388(10053):1603-58. 4. RIVM in opdracht van het Ministerie van Volksgezondheid WeSVMvV, Welzijn en Sport. CBS Gezondheidsenquete 2020; 5. RIVM in opdracht van het Ministerie van VolksgezondheidWeSVMvV, Welzijn en Sport. 2022. 6. Hunter DJ, Schofield D, Callander E. The individual and socioeconomic impact of osteoarthritis. Nat Rev Rheumatol. 2014;10(7):437-41. 7. Rice DA, Kluger MT, McNair PJ, Lewis GN, Somogyi AA, Borotkanics R, et al. Persistent postoperative pain after total knee arthroplasty: a prospective cohort study of potential risk factors. Br J Anaesth. 2018;121(4):804-12. 8. van der List JP, Sheng DL, Kleeblad LJ, Chawla H, Pearle AD. Outcomes of cementless unicompartmental and total knee arthroplasty: A systematic review. Knee. 2017;24(3):497-507. 9. Subramanian G, McAfee JG. A new complex of 99mTc for skeletal imaging. Radiology. 1971;99(1):192-6. 10. Javaid MK, Boyce A, Appelman-Dijkstra N, Ong J, Defabianis P, Offiah A, et al. Best practice management guidelines for fibrous dysplasia/McCune-Albright syndrome: a consensus statement from the FD/MAS international consortium. Orphanet J Rare Dis. 2019;14(1):139. 11. Chapurlat RD, Gensburger D, Jimenez-Andrade JM, Ghilardi JR, Kelly M, Mantyh P. Pathophysiology and medical treatment of pain in fibrous dysplasia of bone. Orphanet J Rare Dis. 2012;7 Suppl 1:S3. 12. van der Bruggen W, Hagelstein-Rotman M, de Geus-Oei LF, Smit F, Dijkstra PDS, Appelman-Dijkstra NM, et al. Quantifying skeletal burden in fibrous dysplasia using sodium fluoride PET/CT. Eur J Nucl Med Mol Imaging. 2020;47(6):1527-37. 13. Konradi A. Fibrous dysplasia patients with and without craniofacial involvement report reduced quality of life inclusive of stigma, depression, and anxiety. Chronic Illn. 2021:17423953211049436. 14. Majoor BCJ, Papapoulos SE, Dijkstra PDS, Fiocco M, Hamdy NAT, Appelman-Dijkstra NM. Denosumab in Patients With Fibrous Dysplasia Previously Treated With Bisphosphonates. J Clin Endocrinol Metab. 2019;104(12):6069-78. 15. Majoor BC, Appelman-Dijkstra NM, Fiocco M, van de Sande MA, Dijkstra PS, Hamdy NA. Outcome of Long-TermBisphosphonate Therapy in McCune-Albright Syndrome and Polyostotic Fibrous Dysplasia. J Bone Miner Res. 2017;32(2):264-76. 16. Collins MT, Kushner H, Reynolds JC, Chebli C, Kelly MH, Gupta A, et al. An instrument to measure skeletal burden and predict functional outcome in fibrous dysplasia of bone. J Bone Miner Res. 2005;20(2):219-26. 17. Blau M, Nagler W, Bender MA. Fluorine-18: a new isotope for bone scanning. J Nucl Med. 1962;3:332-4.